AOD-9604

The FDA briefing evaluates AOD-9604-related substances rather than a finished approved product. It considers the characterization of the ingredients and the clinical evidence available for the proposed use. A review of a bulk substance does not establish that every finished preparation has acceptable quality or effectiveness. ¹

FDA did not evaluate proposed osteoarthritis and osteoporosis uses because the nominations and identified clinical evidence were insufficient for those questions. Those limitations should not be rewritten as proof of cartilage repair or bone benefit. ¹

Ask whether a claim comes from controlled human outcomes or from mechanism, laboratory work or a seller’s description. The product, route, population and follow-up need to match. A general fat-burning phrase hides those details and does not provide a useful clinical estimate.

AOD-9604 is a modified fragment related to part of human growth hormone. It should not be called growth hormone or assumed to reproduce the full hormone's actions. Mechanistic or animal fat-metabolism findings do not establish meaningful human weight loss. Likewise, the absence of expected growth-hormone effects would not by itself prove long-term safety. The exact free base or acetate, route and finished formulation need characterization before evidence can be matched. ¹

FDA's scientific briefing evaluated nominated bulk substances and identified insufficient information for proposed uses and safety questions. A compounding advisory review is not FDA approval, and a seller cannot convert that review into an endorsement. FDA has also noted immunogenicity, peptide-impurity and characterization concerns and serious adverse events with uncertain causality. Uncertainty should be reported directly rather than reframed as no known side effects. ¹

A weight-loss claim needs controlled human outcomes with a defined population, route, duration and comparator. Osteoarthritis, cartilage and bone claims require their own clinical endpoints; evidence proposed for one use cannot be borrowed for another. AOD-9604 combinations with GLP-1 medicines or other peptides are new interventions. Do not infer a dose from animal studies or growth-hormone fragments. People with persistent weight or joint concerns should use established diagnostic and treatment pathways while the evidence remains unresolved. ¹

A certificate of analysis can describe mass or purity for a submitted sample, but it does not by itself establish the exact salt, sequence, sterility, endotoxin level, stability or contents of the vial a patient receives. Even a correctly identified substance would still need clinical efficacy and safety evidence. Product testing and treatment validation are separate questions, and neither should be replaced by seller reputation. ¹